Likewise, Chen et al. (2013) aimed to compare the HOXB13 G84E mutation frequency among subjects of different races/ethnicities from various geographic regions in the world and to assess its risk for developing PCa, in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial. The gene discussed is HOXB13; the disease is posterior cortical atrophy.